Immunohistochemistry was used to assess estrogen receptor (ER), progesterone receptor (PR), HER2 status, and Ki-67 proliferation index, all of which contributed to defining tumor subtype and guiding therapeutic decisions. Here, ERBB2 is linked to neoplasm.